等待开盘 09-20 09:30:00 美东时间
+0.700
+15.22%
Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab.
08-15 00:29
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on SLRN st...
08-14 10:15
HC Wainwright & Co.:维持Acelyrin(SLRN.US)评级,由买入调整至买入评级, 目标价由16.00美元调整至18.00美元。
05-22 18:21
Acelyrin (NASDAQ:SLRN) Thursday announced the appointment of Mina Kim as Chief Executive Officer, succeeding founder Shao-Lee Lin. Kim played a pivotal role in the company's initial public offering an...
05-09 20:42
Acelyrin (NASDAQ:SLRN) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.99) by 24.24 percent.
03-29 11:38
Acelyrin press release (NASDAQ:SLRN): FY GAAP EPS of -$5.43. Cash, cash equivalents and short-term marketable securities totaled $721.3 million at December 31, 2023. More on Acelyrin Acelyrin: Analyzi...
03-29 05:01
Companies in the Healthcare sector have received a lot of coverage today as ana...
03-21 05:11
Acelyrin (NASDAQ:SLRN) shares rose +2.89% to $8.19 on Wednesday, after announcing positive early-stage study data from an ongoing trial of its drug lonigutamab, in treating thyroid eye disease. Lonigu...
03-20 22:09
Gainers: Treasure Global (TGL) +47%. Taysha Gene Therapies (TSHA) +28% Q4 earnings call release Nature's Miracle Holding (NMHI) +23%. PDD Holdings (PDD) +16% soars over 10% on Q4 beat as transacti...
03-20 20:17
An announcement from ACELYRIN, INC. (SLRN) is now available. ACELYRIN, INC. has...
03-20 19:23